Naoki Okubo

526 total citations
21 papers, 397 citations indexed

About

Naoki Okubo is a scholar working on Orthopedics and Sports Medicine, Oncology and Rheumatology. According to data from OpenAlex, Naoki Okubo has authored 21 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Orthopedics and Sports Medicine, 9 papers in Oncology and 9 papers in Rheumatology. Recurrent topics in Naoki Okubo's work include Bone health and osteoporosis research (10 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Bone health and treatments (7 papers). Naoki Okubo is often cited by papers focused on Bone health and osteoporosis research (10 papers), Rheumatoid Arthritis Research and Therapies (8 papers) and Bone health and treatments (7 papers). Naoki Okubo collaborates with scholars based in Japan, United States and Netherlands. Naoki Okubo's co-authors include Yoshiya Tanaka, Toshiyuki Yoneda, Tsutomu Takeuchi, Hisashi Yamanaka, Désirée van der Heijde, Harry K. Genant, Naoki Ishiguro, Sakae Tanaka, Satoshi Soen and Toshitaka Nakamura and has published in prestigious journals such as Annals of the Rheumatic Diseases, Osteoporosis International and Lara D. Veeken.

In The Last Decade

Naoki Okubo

19 papers receiving 393 citations

Peers

Countries citing papers authored by Naoki Okubo

Since Specialization

Citations

This map shows the geographic impact of Naoki Okubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Okubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Okubo more than expected).

Fields of papers citing papers by Naoki Okubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Okubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Okubo. The network helps show where Naoki Okubo may publish in the future.

Co-authorship network of co-authors of Naoki Okubo

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Okubo. A scholar is included among the top collaborators of Naoki Okubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Okubo. Naoki Okubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan 2024 ·Journal of Bone and Mineral Metabolism ·Hisashi Matsushima, Tetsuya Taguchi, (unknown), Naoki Okubo, K. Saito, (unknown), Seiji Fukumoto, Toshio Matsumoto	2
2	Real-world fracture risk, osteoporosis treatment status, and mortality of Japanese non-dialysis patients with chronic kidney disease stages G3–5 2024 ·Clinical and Experimental Nephrology ·(unknown), (unknown), (unknown), Hisako Yoshida, Tetsuo Ito, (unknown), Naoki Okubo, Ayumi Shintani	1
3	Osteoporotic fracture risk in women with breast cancer treated with aromatase inhibitors: a health insurance claims database study in Japan 2024 ·Expert Opinion on Pharmacotherapy ·Tetsuya Taguchi, Hisashi Matsushima, (unknown), Naoki Okubo, Tetsuo Ito, (unknown), Seiji Fukumoto, Toshio Matsumoto	0
4	Safety and effectiveness of denosumab in Japanese patients with rheumatoid arthritis: A 2-year post-marketing surveillance study 2023 ·Modern Rheumatology ·Yoshiya Tanaka, (unknown), (unknown), Naoki Okubo	0
5	Fracture risk associated with glucocorticoid-induced osteoporosis in Japan 2022 ·Journal of Bone and Mineral Metabolism ·Satoshi Soen, (unknown), Naoki Okubo, (unknown), K. Saito, Makiko Kobayashi	9
6	Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study 2021 ·Journal of Bone and Mineral Metabolism ·Sakae Tanaka, (unknown), (unknown), (unknown), (unknown), Naoki Okubo	9
7	Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study 2021 ·The Journal of Rheumatology ·Yoshiya Tanaka, Tsutomu Takeuchi, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde	11
8	Epidemiology of glucocorticoid-induced osteoporosis and management of associated fracture risk in Japan 2021 ·Journal of Bone and Mineral Metabolism ·Satoshi Soen, (unknown), Naoki Okubo, (unknown), K. Saito, Makiko Kobayashi	10
9	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake 2021 ·The Oncologist ·Anna Ozaki, Takaomi Kessoku, Yuki Kasai, (unknown), Naoki Okubo, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Yasushi Honda, Akiko Fuyuki, Takuma Higurashi, Hiroto Ishiki, Masataka Taguri, Shunsuke Oyamada, Noritoshi Kobayashi, Atsushi Nakajima, Yasushi Ichikawa	4
10	Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction 2020 ·RMD Open ·Yoshiya Tanaka, Satoshi Soen, Naoki Ishiguro, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, (unknown), (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde, Tsutomu Takeuchi	7
11	Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status 2020 ·Journal of Bone and Mineral Metabolism ·Toshitsugu Sugimoto, Toshio Matsumoto, Takayuki Hosoi, Masataka Shiraki, Makiko Kobayashi, Naoki Okubo, (unknown), Toshitaka Nakamura	9
12	Case Reports: Transformation of End-Stage Neuroendocrine Tumors With Uncontrollable Liver Metastasis Into a Novel or Additional Functional Phenotype 2020 ·Frontiers in Oncology ·Takaomi Kessoku, Noritoshi Kobayashi, Masato Yoneda, Yuki Kasai, Anna Ozaki, Naoki Okubo, Michihiro Iwaki, Takashi Kobayashi, Tsutomu Yoshihara, Yusuke Kurita, Yasushi Honda, Motohiko Tokuhisa, Hiroto Ishiki, Takashi Hibiya, Satoshi Fujii, Atsushi Nakajima, Yasushi Ichikawa	3
13	Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis 2020 ·Calcified Tissue International ·Naoki Okubo, Shigeyuki Matsui, Toshio Matsumoto, Toshitsugu Sugimoto, Takayuki Hosoi, (unknown), (unknown), (unknown), Masataka Shiraki, Toshitaka Nakamura	4
14	Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial 2019 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde	108
15	Safety and Efficacy of Long‒term Denosumab Treatment in Japanese Patients with Osteoporosis in Daily Clinical Practice：An Interim Analysis of a Post‒marketing Surveillance Study 2018 ·Sakae Tanaka, (unknown), (unknown), (unknown), (unknown), Naoki Okubo	1
16	Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study 2018 ·Lara D. Veeken ·Naoki Ishiguro, Yoshiya Tanaka, Hisashi Yamanaka, Toshiyuki Yoneda, (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde, Tsutomu Takeuchi	18
17	Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis 2017 ·Bone Reports ·Teruki Sone, Naohiro Kon, (unknown), Naoki Okubo, (unknown), Yutaka Nakayama, Masao Fukunaga, Masako Ito, Toshitaka Nakamura	7
18	SAT0186 Effects of denosumab, a subcutaneous rankl inhibitor, on the progression of structural damage in japanese patients with rheumatoid arthritis treated with csdmards: results from the 12-month double blind phase 3, desirable study 2017 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, (unknown), Naoki Okubo, H K Genant, D. van der Heijde	2
19	Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose–response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial 2016 ·Annals of the Rheumatic Diseases ·Tsutomu Takeuchi, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Toshiyuki Yoneda, (unknown), Naoki Okubo, Harry K. Genant, Désirée van der Heijde	131
20	Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT) 2014 ·Osteoporosis International ·Toshitsugu Sugimoto, Toshio Matsumoto, Takayuki Hosoi, T. Miki, Itsuo Gorai, Hideki Yoshikawa, Yoshiya Tanaka, Sakae Tanaka, Masao Fukunaga, Teruki Sone, Tsuyoshi Nakano, M. Ito, Shigeyuki Matsui, Toshiyuki Yoneda, (unknown), Ken Watanabe, (unknown), Naoki Okubo, Masataka Shiraki, Toshitaka Nakamura	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact